company background image
BIIB logo

Biogen NasdaqGS:BIIB Stock Report

Last Price

US$219.40

Market Cap

US$31.9b

7D

-4.6%

1Y

-18.1%

Updated

18 Mar, 2024

Data

Company Financials +

BIIB Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

BIIB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Biogen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$219.40
52 Week HighUS$319.76
52 Week LowUS$215.35
Beta-0.024
1 Month Change0.15%
3 Month Change-12.83%
1 Year Change-18.11%
3 Year Change-19.44%
5 Year Change-0.39%
Change since IPO7,015.68%

Recent News & Updates

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Recent updates

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Apr 14
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Mar 27
Is Biogen (NASDAQ:BIIB) A Risky Investment?

Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)

Jan 14
Calculating The Intrinsic Value Of Biogen Inc. (NASDAQ:BIIB)

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Dec 25
Is Biogen (NASDAQ:BIIB) A Risky Investment?

Shareholder Returns

BIIBUS BiotechsUS Market
7D-4.6%-2.1%-0.1%
1Y-18.1%10.4%28.4%

Return vs Industry: BIIB underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: BIIB underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement3.7%
Biotechs Industry Average Movement11.9%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: BIIB has not had significant price volatility in the past 3 months.

Volatility Over Time: BIIB's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,570Chris Viehbacherhttps://www.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market capUS$31.89b
Earnings (TTM)US$1.16b
Revenue (TTM)US$9.84b

27.5x

P/E Ratio

3.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIB income statement (TTM)
RevenueUS$9.84b
Cost of RevenueUS$2.53b
Gross ProfitUS$7.30b
Other ExpensesUS$6.14b
EarningsUS$1.16b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)7.99
Gross Margin74.24%
Net Profit Margin11.81%
Debt/Equity Ratio46.9%

How did BIIB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.